EU OKs Celgene pancreatic cancer drug


The European Commission has approved Celgene's (CELG) Abraxane treatment for metastatic pancreatic cancer when used in combination with the chemotherapy gemcitabine.

Abraxane is the first drug in seven years to be approved in Europe for the disease.

Celgene intends to start selling the therapy in the coming months according to local requirements. (PR)

From other sites
Comments (3)
  • RHMASSING
    , contributor
    Comments (592) | Send Message
     
    This news makes GS's downgrade yesterday like a farce!
    7 Jan 2014, 08:00 AM Reply Like
  • zorro2828
    , contributor
    Comments (740) | Send Message
     
    Amen to that.. BUYING OPPORTUNITY.. HUGE
    7 Jan 2014, 08:13 AM Reply Like
  • hneumann
    , contributor
    Comments (630) | Send Message
     
    Yes, and GS is alone. All other analysts who changed lately, raised PT.
    7 Jan 2014, 08:15 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs